**Star Health and Allied Insurance Q3 Results 2025**
On January 28, 2025, Star Health and Allied Insurance announced its Q3 results, showcasing a year-on-year topline growth of 15.72%. However, the company faced a substantial decline in profit, which fell by 25.7% year-on-year to ₹215.14 crore, while revenues reached ₹3,999.63 crore.
When compared to the previous quarter, revenue exhibited a modest increase of 2.23%, whereas profits surged by an impressive 93.31%, underscoring the volatility in the company’s financial performance. The company also reported a decrease in selling, general, and administrative expenses, which declined by 6.22% quarter-on-quarter but rose by 5.74% year-on-year, indicating a tightening of operational costs in the recent quarter.
Operating income experienced a staggering quarter-on-quarter increase of 30,788.89%, although it saw a year-on-year decline of 47.62%, reflecting fluctuations in earnings performance across different periods. The earnings per share (EPS) for Q3 was reported at ₹3.62, marking a year-on-year decrease of 25.51%, which may raise concerns among investors focused on profitability metrics.
In the stock market, Star Health and Allied Insurance has faced a challenging period, with returns of -3.97% over the past week, -27.74% over the last six months, and -6.34% year-to-date. The company currently holds a market capitalization of ₹26,142.92 crore, with a 52-week high of ₹647 and a low of ₹438, indicating significant price volatility.
As of January 29, 2025, among 20 analysts covering the company, the ratings are mixed: 2 analysts have issued a Strong Sell rating, 4 a Sell rating, 2 a Hold rating, 4 a Buy rating, and 8 a Strong Buy rating. The consensus recommendation on this date is to Buy, suggesting that despite recent challenges, analysts maintain a positive outlook on the company’s future performance.
**Star Health and Allied Insurance Financials**
| Period | Q3 (FY25) | Q2 (FY25) | Q-o-Q Growth | Q3 (FY24) | Y-o-Y Growth |
|———————-|———–|———–|————–|———–|————–|
| Total Revenue | 3999.63 | 3912.28 | +2.23% | 3456.25 | +15.72% |
| Selling/General/Admin Expenses Total | 466.52 | 497.45 | -6.22% | 441.19 | +5.74% |
| Total Operating Expense | 3860.63 | 3911.83 | -1.31% | 3190.88 | +20.99% |
| Operating Income | 1390.45 | – | +30788.89% | 265.37 | -47.62% |
| Net Income Before Taxes | 286.96 | 148.8 | +92.85% | 387.67 | -25.98% |
| Net Income | 215.14 | 111.29 | +93.31% | 289.55 | -25.7% |
| Diluted Normalized EPS | 3.62 | 1.87 | +93.58% | 4.86 | -25.51% |
